This virtual public workshop provided a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and to highlight opportunities ...

The goal of this collaborative is to examine and highlight the bottlenecks to drug research and development (R&D) for highly prevalent chronic diseases and develop a set of key considerations and ...

Massimo Radaelli, PhD, is a European pharmaceutical industry leader and entrepreneur who has devoted more than 30 years to the innovation of therapies to treat rare diseases. He is President and CEO ...

Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025 CORALVILLE, ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In a move that could dramatically reshape the landscape for rare ...

The FDA is seeking public input on drug repurposing efforts aimed at expanding treatment options for diseases tied to unmet medical needs. The agency said identifying new uses for FDA-approved drugs ...

The FDA approved new treatments for HIV, RSV, and allergic fungal rhinosinusitis, alongside a wound care gel recall, marking a busy week in infectious disease regulation. At the same time, major ...

Your editorial on “Why Vinay Prasad Had to Go at FDA” should be a wake-up call for anyone who cares whether federal bureaucrats get to decide if promising new medicines are available to desperately ...

According to the Autoimmune Association, approximately 50 million Americans live with an autoimmune disease, yet these ...

Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security. As traditional drug-delivery approaches continue to face limitations, alternative methods ...